LONDON/PARIS Britain has signed a deal for up to 60 million doses of a potential coronavirus vaccine being developed by Sanofi and GlaxoSmithKline (GSK), it said on Wednesday, its latest such arrangement as the race to tame the pandemic heats up.
PARIS Sanofi raised its 2020 earnings forecast on Wednesday after its second-quarter results were boosted by cost cuts and the sale of most of its 20.6% stake in U.S. company Regeneron, although revenue was hit by the coronavirus crisis.
- von Matthias Blamont und Gwénaëlle Barzic und Arno Schuetze
PARIS/FRANKFURT Sanofi is starting preparations for a stock market listing of its active ingredients business as the French drugmaker pushes ahead with a strategy focusing on its more profitable businesses, sources told Reuters.
PARIS French drugmaker Sanofi, which employs more than 100,000 people worldwide, confirmed on Friday it will axe up to 1,680 jobs in Europe to cut costs and lift profits.
PARIS, June 26 Sanofi said on Friday
it is planning to slash up to 1,680 jobs in Europe, confirming
what two sources familiar with the matter had previously told
PARIS Sanofi is considering cutting hundreds of jobs and will discuss potential steps with staff representatives over the coming days, five sources said on Thursday, the latest move by the French drugmaker's chief executive Paul Hudson to cut costs. Management will meet staff representatives on Friday and Monday next week to outline a restructuring plan, five sources familiar with the matter told Reuters. They declined to be identified as the plan is still confidential.
PARIS French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated. | Video